Concurrent chemoradiation is a standard option for locally advanced pancreatic cancer (LAPC). Concurrent conventional radiation with full-dose gemcitabine has significant toxicity. Stereotactic body radiation therapy (SBRT) may provide the opportunity to administer radiation in a shorter time frame with similar efficacy and reduced toxicity. This Pilot study assessed the safety of concurrent full-dose gemcitabine with SBRT for LAPC.
Patients received gemcitabine, 1000 mg/m2 for 6 cycles. During week 4 of cycle 1, patients received SBRT (25 Gy delivered in five consecutive daily fractions of 5 Gy prescribed to the 75-83% isodose line). Acute and late toxicities were assessed using NIH CTCAE v3. Tumor response was assessed by RECIST. Patients underwent an esophagogastroduodenoscopy at baseline, 2, and 6 months to assess the duodenal mucosa. Quality of life (QoL) data was collected before and after treatment using the QLQ-C30 and QLQ-PAN26 questionnaires.
Between September 2009 and February 2011, 11 patients enrolled with one withdrawal during radiation therapy. Patients had grade 1 to 2 gastrointestinal toxicity from the start of SBRT to 2 weeks after treatment. There were no grade 3 or greater radiation-related toxicities or delays for cycle 2 of gemcitabine. On endoscopy, there were no grade 2 or higher mucosal toxicities. Two patients had a partial response. The median progression free and overall survival were 6.8 and 12.2 months, respectively. Global QoL did not change between baseline and immediately after radiation treatment.
SBRT with concurrent full dose gemcitabine is safe when administered to patients with LAPC. There is no delay in administration of radiation or chemotherapy, and radiation is completed with minimal toxicity.
Pancreatic cancerGemcitabineRadiationStereotactic body radiation therapySBRTCyberKnifeQuality of lifeQLQ-C30QLQ-PAN26Upper endoscopy
Quality of life (QoL) is of paramount importance when cure is not achievable, as is currently the case with locally advanced pancreatic cancer (LAPC). In the United States, concurrent chemoradiation therapy is commonly considered the standard of care for LAPC patients, but outcomes are still poor. Randomized clinical trials of chemoradiation vs. chemotherapy alone have shown mixed results, with some trials showing a survival benefit with chemoradiation [1–4] and others demonstrating that is has a negative impact on overall survival [5, 6]. Furthermore, in trials in which there was a survival advantage, toxicity was often higher in the chemoradiation arm [1, 3, 4]. Therefore, clinicians and patients must weigh the small potential gain in overall survival versus the potential adverse effects with chemoradiation.
Traditionally, chemoradiation trials include the use of conventional external beam radiation. This technique uses large radiation fields that deliver a high percentage of the prescription dose to surrounding critical structures possibly leading to significant toxicity and decreased quality of life. When irradiating abdominal tumors with conventional external beam radiation, strict adherence to normal structure dose constraints may limit the delivery of the intended radiation dose to the tumor and potentially result in premature local failure and death. Conversely, delivering high doses of radiation to adjacent critical structures without strict dose constraints increases the risk of late radiation induced complications. Intensity-modulated radiation therapy (IMRT) has made advances over 3D conformal treatment in protecting critical structures and reducing toxicity [7, 8]; however grade 3 and 4 toxicities are still reported and treatment breaks are required that may reduce the treatment’s effectiveness. Tumor motion due to respiration  and unpredictable gastrointestinal distention , require large IMRT planning target volume expansions that limit the maximum prescription dose. Furthermore, daily IMRT treatments for approximately six weeks can be taxing to these ill patients and their families and society . SBRT may prevent local progression of disease while sparing nearby critical structures, thus providing an improved durable QoL. Furthermore, SBRT is an appealing option for LAPC since it allows reduced treatment times. Previous studies have investigated SBRT (25 Gy in one fraction) as a boost to IMRT with concurrent 5-FU, and SBRT monotherapy (25 Gy in one fraction) with gemcitabine [12, 13]. In both of these trials, local control was excellent; however, late duodenal toxicity was significant, and was related to the amount of duodenum irradiated . Median overall survival was comparable to modern expected outcomes [4, 15, 16]. In an effort to decrease late duodenal toxicity, we and others [17–20], have examined the use of fractionated SBRT with full dose gemcitabine. Here, we report the results of our feasibility trial.
Patients with biopsy-proven, non-metastatic, unresectable pancreatic adenocarcinoma who had an adequate performance status and normal hepatic and renal function were eligible for enrollment on this study. Unresectable disease was defined as any greater than 180° encasement of the celiac, superior mesenteric, hepatic, or gastroduodenal arteries, or greater than 2 cm involvement of the portal or splenic veins, or any venous tumor thrombus. Patients with duodenal mucosal involvement (at time of initial endoscopy) were excluded. The Georgetown University institutional review board approved this study and all patients provided informed written consent.
Figure 1 provides a schematic overview of patient treatment. Eligible patients first underwent an esophagogastroduodenoscopy with endoscopic ultrasound (EGD/EUS) with placement of gold fiducial markers required for SBRT. Gemcitabine, 1000mg/m2, was delivered on day 1 and day 8 (cycle 1, weeks 1 and 2 of gemcitabine). Prior to day 15 (cycle 1, week 3 of gemcitabine), patients underwent a CT scan for SBRT treatment planning. Patients then received day 15 gemcitabine (cycle 1, week 3), and during the subsequent “off” week from chemotherapy (cycle 1, week 4) the patients received SBRT. Cycle 2 of gemcitabine was administered without a planned treatment delay, followed by restaging scans and EGD/EUS to assess tumor response and acute mucosal toxicity. Patients, who were tolerating therapy and without progression as determined by RECIST criteria , continued gemcitabine with restaging scans every two cycles, to a maximum of 6 cycles. One additional EGD/EUS was performed after 6 cycles to assess late toxicities of SBRT.
SBRT treatment was delivered with the CyberKnife (Accuray Incorporated, Sunnyvale, CA) which uses real time tumor tracking and requires 3 visible, non-collinear fiducials on the orthogonal x-ray images . Three to five gold fiducials were placed endoscopically in the pancreatic mass as previously described . Seven days after fiducial placement, fine-cut (1.25 mm) treatment planning CT’s with oral and IV contrast were obtained during a full inhalation breath hold.
The gross target volume (GTV) included the pancreatic mass (Figure 2). The SBRT planning target volume (PTV) equaled the GTV plus the adjacent vasculature (AV) without expansion. The AV is the area of vasculature involvement  and generally included the mesopancreas and posterior nodal regions (posterior pancreaticoduodenal, superior mesenteric, and para-aortic nodes) at the level of the pancreatic mass. Surgical series have demonstrated a high probability of metastases to these regions with 32.31%, 15.85 %, and 10.92%, respectively . Furthermore, the mesopancreas is the primary site for an R1 resection . Therefore, this elective volume was included in increase the probability of an R0 resection if any patients were deemed resectable after chemoradiation. Given the sub-millimeter precision of CyberKnife treatment , no uniform expansion was added to correct for set-up inaccuracy. Instead the initial contours of the GTV were generous because computed tomography scans significantly under-represent pancreatic tumor size . SBRT with respiratory tracking was administered as previously described for lung tumors . The prescription dose was 25 Gy delivered to the PTV in 5 fractions of 5 Gy over 5 days. The volume of the PTV receiving 25 Gy, termed the V25 Gy, was to be at least 95%. Variations of the V25 Gy that were less than 95%, but greater than or equal to 90%, were considered minor variations; whereas variations to the V25 Gy that were less than 90% were considered major variations. The prescription isodose line was limited to ≥ 75% which restricted the maximum tumor dose to 133% of the prescription dose. The duodenal and adjacent bowel volumes receiving 25 Gy were limited to < 1 cc. Variations were considered minor if the V25 Gy was ≥ 1 cc and < 2 cc; variations were considered major if the V25 Gy was > 2 cc (Table 1).
Radiation treatment parameters
Other Bowel (V25Gy)
Mean percent target coverage, prescription isodose line and critical structure dose/volume results and minor and major variations from protocol.
Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. Due to the lack of a systematic endoscopic grading system for radiation induced mucosal injury, a previously developed descriptive based scoring system  was used to evaluate for extent of telangiectasia, congested mucosa, ulceration, stricture and necrosis.
Quality of life assessment
All patients were asked to complete two quality of life questionnaires: the EORTC QLQ-C30 version 3 and EORTC QLQ-PAN26, on the first day of each chemotherapy cycle. The QLQ-C30 measures generic health status. QLQ-PAN26 is a pancreatic cancer treatment specific instrument that assesses patient function and bother .
Baseline characteristics and adverse events were tabulated. Adverse events were described for each symptom according to Wachter, et al. and the NCI CTCAE version 3.0. Each symptom was counted once per patient at the highest grade it occurred. Progression-Free Survival (PFS) was calculated as the date gemcitabine was started to the date of progression or death, whichever came first. Overall survival (OS) was calculated from the start date of gemcitabine to date of death. Since patients were followed until death, no censoring occurred for PFS or OS. OS and PFS were calculated using the Kaplan-Meier method . Median OS and PFS times were reported with 95% confidence intervals (CI). Local control was determined by continued growth of the primary on serial radiologic imaging. Wilcoxon rank sum test was used to assess QoL score changes.
Results and discussion
Patient and tumor characteristics
Fourteen patients were screened and three patients were not enrolled for the following reasons: 1) Identification of metastatic disease; 2) Liver transaminitis; and 3) Inability to endoscopically place fiducials due to a previously placed duodenal stent. One patient, who was 81 years of age, withdrew due to significant decrease in performance status after just two radiation treatments so an 11th patient was enrolled for 10 evaluable patients. These patients were treated over a period extending from September 2009 to February 2011 (Table 2) and were followed until death. The mean age at enrollment was 62.5 years (range 50 – 79 years). Nine patients had an ECOG performance status (PS) 1 and one patient was an ECOG PS 0. All the tumors involved the pancreatic head or body and six patients also had clinically involved lymph nodes.
Head & Body
Withdrew before completing radiation
Screening failure due to metastatic disease
Screening failure due to elevated liver function.
Screening failure due to inability to place fiducials.
All patients completed SBRT as prescribed. The mean PTV was large with a mean volume of 360 cc (range, 154 cc – 548 cc) and the mean GTV was 175 cc (range, 103 – 336 cc) (Table 1). Radiation was delivered to a mean prescription isodose line of 78% (range, 75% - 83%) in 5 treatments (Table 1). The mean percent target coverage was 95.42%. Treatment plans were conformal with a mean new conformity index (the target volume multiplied by the prescription isodose volume divided by the target volume covered by prescription isodose volume squared ) of 1.39. Plans were inhomogeneous by design (mean homogeneity index of 1.28) to minimize dose to adjacent critical structures. There were no major protocol variations; one minor protocol variation occurred when 1.0 cc of duodenum received 25 Gy (Table 1).
From the start of SBRT and for 1–2 weeks thereafter, patients generally exhibited grade 1–2 nausea and abdominal cramping, but there were no grade 3 radiation-related acute toxicities, and cycle 2 of gemcitabine was not delayed. Serial endoscopy showed 60% of patients had asymptomatic, small mucosal ulcerations (Grade 1) at 2 months. Of the five patients who completed endoscopy at six months one patient had residual grade one mucosal congestion. There were no grade 2 or higher mucosal toxicities.
Overall, 8 of 10 patients completed 6 cycles of gemcitabine, although all patients required dose reductions or schedule modifications, mostly due to myelosuppression from the chemotherapy. Of the two patients who did not complete all six cycles, one patient became critically ill during cycle three, was admitted for sepsis and taken off study. The other patient progressed with distant metastases after chemotherapy cycle five and was changed to an alternative chemotherapy regimen.
All patients were followed until death. Two patients had a partial response by RECIST. None of the patients were rendered resectable. All but one patient experienced disease progression by RECIST with a median time to progression of 6.8 months (95% CI: 2.8, 10.3 months). Four patients experienced local progression as the first site of failure and a total of six patients experienced local progression before death (Table 3). The median survival was 12.2 months (95% CI: 4.4, 15.2 months) (Figure 3). Of the patients who completed all cycles, one patient received maintenance chemotherapy with capecitabine and three patients received salvage chemotherapy and/or conventional radiation therapy (39 cGy in 1.8 Gy fractions) at the time of progression. Patients who did not receive salvage therapy either opted not to or were too sick to do so (Table 3).
Individual clinical outcomes
Best response (RECIST)
Time to progression (days)
First site of progression
Time to death (days)
Local + distant
Capecitabine (maintenance); Radiation
Erlotinib with gemcitabine
Progressed on gemcitabine, switched to lapatinib + capecitabine
Quality of life
Of the eight patients who received all six chemotherapy cycles, only four patients completed both the EORTC QTC 30 and PAN 26 questionnaires for all chemotherapy cycles, which limited the analysis to the first three chemotherapy cycles. QoL scores immediately after SBRT showed a statistically significant increase from baseline for fatigue, nausea/vomiting (N/V) and anorexia (p < 0.05). The declines in fatigue and anorexia QoL were no longer statistically different from baseline by chemotherapy cycle 3. Symptoms did not improve significantly after radiation therapy; however, there was a trend towards improved back pain, night pain and abdominal discomfort. Global QoL did not change significantly from baseline due to radiation treatment (Figure 4).
In pancreatic cancer, improved methods of controlling the primary cancer are needed as local progression adversely affects the length and quality of life. Dose escalation with standard external beam radiation therapy has been attempted . However, the inability to limit normal tissue doses led to severe life-threatening toxicity. On the other hand, standard radiation treatment for 5–6 weeks prolongs treatment time and delays administration of systemic therapy. Recent data suggest that large radiation fraction sizes are radio-biologically favorable over lower fraction sizes in slow growing tumors such as pancreatic cancer [34, 35]. This is supported by trials that achieved improved pancreatic cancer local control rates by utilizing large fraction sizes with intraoperative radiation therapy or brachytherapy [36–42]. Analysis of these data suggested that radiobiologic dose escalation to the tumor volume could improve local control in pancreatic cancer.
Gemcitabine is a potent pancreatic cancer radiosensitizer . As previously shown, by the Eastern Cooperative Oncology Group, in patients with LAPC, concurrent gemcitabine at a reduced dose (600 mg/m2) and radiation (50.4 Gy in 28 fractions) provided survival benefit over gemcitabine (1000 mg/m2) alone (4). Furthermore, full dose gemcitabine (1000 mg/m2/week) with concurrent radiation therapy has been shown to be feasible and safe with the omission of elective nodal irradiation and radiation dose reductions . The combination of full dose gemcitabine with radiation therapy should enhance local and systemic tumor control.
In our study, patients received full dose gemcitabine (1000 mg/m2) and concurrent SBRT with an included elective nodal volume The radiation dose given was 25 Gy in five consecutive fractions, which is an equivalent dose in 2 Gy fractions of approximately 40 Gy. We felt that this would be a safe but effective dose drawing from the University of Michigan’s IMRT dose escalation trial. In their trial the MTD was determined to be 36 Gray given in 2.4 Gray fractions, which is equivalent to 41.4 Gray in 1.8 Gray fractions . Furthermore, the inhomogenity is much greater with SBRT than IMRT and consequently the central tumor dose is significantly higher than the prescription dose to the periphery.
Hypofractionated stereotactic body radiation therapy was completed in one week in all patients. Critical organs including the bowel, liver, spinal cord, and kidneys were spared. There were no grade 3 or 4 acute toxicities secondary to radiation and the initiation of the second cycle of chemotherapy was not delayed. Our protocol had strict duodenal dose restrictions and additionally monitoring for late toxicity by endoscopy was performed. With our dose limitations no late toxicity was observed. Chemotherapy toxicity from full dose gemcitabine was as expected with the majority secondary to adverse hematologic effects. However, our local control was lower than that achieved with a single fraction of 25 Gy. This is despite the fact that our patients received concurrent full dose (1000 mg/m2) gemcitabine rather than sequential chemotherapy. This may be due to the relatively low biological effective dose used in this trial.
Despite the lower local control, our median progression free survival and overall survival of 6.8 and 12.2 months are comparable to contemporary chemoradiation trials. Quality of life scores were difficult to interpret due to the small number of patients that completed all the questionnaires. This could have biased the results since patients who progressed were taken off study and did not complete the questionnaires and patients too ill to complete the questionnaires would most likely report lower QOL scores.
Our results from this pilot study demonstrate the feasibility and tolerability of delivering SBRT with concurrent full dose gemcitabine. Unfortunately, local and distant progression remains the predominant patterns of failure for these patients. Nonetheless, SBRT remains a useful tool to optimize available treatment for patients with tumors in close proximity to critical structures while maintaining QOL. Additional studies combining SBRT with regimens that have been proven to improve the control of systemic disease, such as FOLFIRINOX, are also being evaluated .
We are planning to conduct a Phase II trial to confirm the efficacy of this treatment. While outcomes were comparable to contemporary trials, this study only included ten patients. Furthermore, the SBRT dose used in this trial is currently lower than what our institution is safely using at this time. With the low toxicity profile experienced by patients on this trial we will increase the SBRT dose and our future trial will most likely treat patients in five consecutive fractions of 6 Gy per fraction. This will hopefully provide improved local control. While there is still an issue with controlling distant disease, local tumor progression leads to significant morbidity.
This trial was funded by the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers and supported by NIH Grant P30CA051008.
Quality of life
Locally advances pancreatic cancer
Stereotactice body radiation therapy
Intensity-modulated radiation therapy
Gross target volume
Planning target volume
Department of Radiation Oncology, Georgetown University Hospital
Lombardi Comprehensive Cancer Center, Georgetown University
Department of Biostatistics, University of Texas MD Anderson Cancer Center
Division of Gastroenterology, Department of Medicine, Georgetown University Hospital
Department of Radiology, Georgetown University Hospital
University Surgical Unit, Southampton University Hospitals
Department of Surgery, Georgetown University Hospital
Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.Cancer 1981, 48:1705–1710.PubMedView Article
Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.Lancet 1969, 2:865–867.PubMedView Article
Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.J Natl Cancer Inst 1988, 80:751–755.View Article
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.J Clin Oncol 2011, 29:4105–4112.PubMedView Article
Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study.Ann Oncol 2008, 19:1592–1599.PubMedView Article
Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study.J Clin Oncol 1985, 3:373–378.PubMed
Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF: Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.Int J Radiat Oncol Biol Phys 2011, 79:158–162.PubMedView Article
Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.Int J Radiat Oncol Biol Phys 2004, 59:445–453.PubMedView Article
Feng M, Balter JM, Normolle D, Adusumilli S, Cao Y, Chenevert TL, Ben-Josef E: Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution.Int J Radiat Oncol Biol Phys 2009, 74:884–891.PubMedView Article
Horst E, Micke O, Moustakis C, Schuck A, Schafer U, Willich NA: Conformal therapy for pancreatic cancer: variation of organ position due to gastrointestinal distention–implications for treatment planning.Radiology 2002, 222:681–686.PubMedView Article
Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, Koong AC: Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.Cancer 2012, 118:1119–1129.PubMedView Article
Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 2005, 63:320–323.PubMedView Article
Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J: Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 2008, 72:678–686.PubMedView Article
Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC: A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer.Int J Radiat Oncol Biol Phys 2010, 78:1420–1426.PubMedView Article
Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.Int J Radiat Oncol Biol Phys 2007, 68:801–808.PubMedView Article
Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ: Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98–12.Am J Clin Oncol 2004, 27:51–56.PubMedView Article
Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 2010, 78:735–742.PubMedView Article
Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M: Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.Int J Radiat Oncol Biol Phys 2011, 81:e615–622.PubMedView Article
Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S: Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.J Gastrointest Surg 2010, 14:1547–1559.PubMedView Article
Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G: Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.Ann Surg Oncol 2010, 17:2092–2101.PubMedView Article
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer 2009, 45:228–247.PubMedView Article
Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR Jr: The CyberKnife robotic radiosurgery system in 2010.Technol Cancer Res Treat 2010, 9:433–452.PubMed
Pishvaian AC, Collins B, Gagnon G, Ahlawat S, Haddad NG: EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies.Gastrointest Endosc 2006, 64:412–417.PubMedView Article
Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS, Haken RK, Ben-Josef E: Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions.Med Phys 2007, 34:521–529.PubMedView Article
Sun W, Leong CN, Zhang Z, Lu JJ: Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence.Radiat Oncol 2010, 5:28.PubMedView Article
Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, Becker H, Ghadimi BM: The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials.Langenbecks Arch Surg 2010, 395:451–458.PubMedView Article
Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS: Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning.Int J Radiat Oncol Biol Phys 2011, 80:1383–1390.PubMedView Article
Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, McRae DA, Zhang Y, Yousefi S, Levy E: Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors.Radiat Oncol 2007, 2:39.PubMedView Article
Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R: Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma.Radiother Oncol 2000, 54:11–19.PubMedView Article
Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C: Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.Eur J Cancer 1999, 35:939–941.PubMedView Article
Kaplan E, Meier P: Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958, 53:457–481.View Article
Nakamura JL, Verhey LJ, Smith V, Petti PL, Lamborn KR, Larson DA, Wara WM, McDermott MW, Sneed PK: Dose conformity of gamma knife radiosurgery and risk factors for complications.Int J Radiat Oncol Biol Phys 2001, 51:1313–1319.PubMedView Article
Ceha HM, Van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, Phoa SS, Gonzalez Gonzalez D: Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma.Cancer 2000, 89:2222–2229.PubMedView Article
Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.Cancer 1988, 61:1110–1116.PubMedView Article
Gunderson LL, Martin JK, Kvols LK, Nagorney DM, Fieck JM, Wieand HS, Martinez A, O'Connell MJ, Earle JD, McIlrath DC: Intraoperative and external beam irradiation +/− 5-FU for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 1987, 13:319–329.PubMedView Article
Mohiuddin M, Regine WF, Stevens J, Rosato F, Barbot D, Biermann W, Cantor R: Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.J Clin Oncol 1995, 13:2764–2768.PubMed
Garton GR, Gunderson LL, Nagorney DM, Donohue JH, Martin JK, McIlrath DC, Cha SS: High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 1993, 27:1153–1157.PubMedView Article
Shipley WU, Nardi GL, Cohen AM, Ling CC: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection.Cancer 1980, 45:709–714.PubMedView Article
Shipley WU, Tepper JE, Warshaw AL, Orlow EL: Intraoperative radiation therapy for patients with pancreatic carcinoma.World J Surg 1984, 8:929–934.PubMedView Article
Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE: Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.Int J Radiat Oncol Biol Phys 1988, 14:79–84.PubMedView Article
Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS: Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.Int J Radiat Oncol Biol Phys 1996, 34:867–872.PubMedView Article
McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.J Clin Oncol 2001, 19:4202–4208.PubMed
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med 2011, 364:1817–1825.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.